SCHEMBL17048256

SCHEMBL17048256

COc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2c(F)c1C1CCN(C2COC2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 20/20 1.00
DAPK3 O43293 1/20 0.64
INSR P06213 1/20 0.64
INSRR P14616 1/20 0.64
LTK P29376 1/20 0.64
CLK1 P49759 1/20 0.64
DAPK1 P53355 1/20 0.64
MERTK Q12866 1/20 0.64
DAPK2 Q9UIK4 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17048257 0.98 ALK (0.96) ALKDAPK3INSRINSRRLTK
SCHEMBL17048388 0.93 ALK (1.00) ALKDAPK3INSRINSRRLTK
SCHEMBL18589157 0.91 ALK (0.83) ALKDAPK3INSRINSRRLTK
SCHEMBL17048359 0.89 ALK (1.00) ALKDAPK3INSRINSRRLTK
SCHEMBL17048283 0.89 ALK (1.00) ALKDAPK3INSRINSRRLTK
SCHEMBL18589071 0.88 ALK (0.79) ALKDAPK3INSRINSRRLTK
SCHEMBL17048360 0.87 ALK (0.95) ALKDAPK3INSRINSRRLTK
SCHEMBL20182828 0.86 ALK (0.83) ALKDAPK3INSRINSRRLTK
SCHEMBL17048124 0.85 ALK (1.00) ALKDAPK3INSRINSRRLTK
SCHEMBL17048241 0.84 ALK (1.00) ALKDAPK3INSRINSRRLTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3110815-B1 INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS JIANGSU ASCENTAGE BIOMED DEV INC (CN) 2020-02-19 EP disclosed
EP-3110815-B1 INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS JIANGSU ASCENTAGE BIOMED DEV INC (CN) 2020-02-19 EP disclosed
US-9783539-B2 Indoloquinolone compounds as anaplastic lymphoma kinase (ALK) inhibitors JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) 2017-10-10 US disclosed
US-9783539-B2 Indoloquinolone compounds as anaplastic lymphoma kinase (ALK) inhibitors JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) 2017-10-10 US disclosed
US-20170066761-A1 INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) 2017-03-09 US disclosed
US-20170066761-A1 INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) 2017-03-09 US disclosed
EP-3110815-A1 INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS Jiangsu Ascentage Biomed Development Inc. (CN) 2017-01-04 EP disclosed
WO-2015127629-A1 INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) 2015-09-03 WO disclosed
WO-2015127629-A1 INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) 2015-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170066761-A1 INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS ALK, BCL6, BCL6B ALK 1/4885DAPK3 215/4885INSR 724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.